Nature QI, 11th March 2019. GTN Co-Authored Paper Published in Nature Quantum Information. Forbes, 13th Feb 2019. GTN & CEO Noor Shaker named as one of Deep Knowledge Analytics' Top 100 AI Leaders in Drug Discovery & Advanced Healthcare.
CEO / Co-Founder Noor Shaker. Before GTN Noor was an assistant professor in ML at Aalborg University in Copenhagen. She has more than 50 publications, 1500+ citations and has co-authored a book on generative methods.
A paper on Hierarchical Quantum Classifiers co-authored by Vid Stojevic, CTO of GTN, has been published in Nature Quantum Information. Quantum circuits with hierarchical structure have been used to perform binary classification of classical data encoded in a quantum state.
29th Nov 2018- We are excited to announce our partnership with C4X Discovery Holdings plc (“C4XD”), a pioneering drug discovery company, initially focusing on identifying potential small molecule hits against a high-value neurodegeneration target. Artificial Intelligence is expected to revolutionise the drug discovery industry. GTN is at the forefront of the field, using deep-learning ...
A consortium of nine universities and six companies has received £59,463 aimed at boosting the representation of women, disabled people, LGBT+, and people from Black andMinority Ethnic backgrounds in Engineering and Physical Sciences in the North of England.
What We Do | Applying AI to Drug Discovery and Development ...
BenevolentAI’s systems, researchers, designers, engineers and scientists are able to learn through each experimental loop, and in every part of the drug development process, accelerating as they go. Our unique strength comes from this end-to-end approach, combined with a relentless pursuit of scient